Base de dados : MEDLINE
Pesquisa : D10.251.355.255.100.450.855 [Categoria DeCS]
Referências encontradas : 4085 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 409 ir para página                         

  1 / 4085 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25707327
[Au] Autor:Jana B; Jaroszewski JJ; Czarzasta J; Markiewicz W
[Ad] Endereço:Division of Reproductive Biology, Department of Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research of the Polish Academy of Sciences, Olsztyn, Poland. Electronic address: b.jana@pan.olsztyn.pl.
[Ti] Título:The influence of leukotrienes C4 and D4 on the contractility of an inflamed porcine uterus.
[So] Source:Theriogenology;83(8):1328-37, 2015 May.
[Is] ISSN:1879-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The effect of leukotriene (LT) C4 (LTC4) and LTD4 on the contractility of an inflamed porcine uterus was investigated. On Day 3 of the estrous cycle (Day 0 of the study), either saline or Escherichia coli suspension was injected into each uterine horn. Although acute endometritis developed in all bacteria-inoculated gilts, a severe acute endometritis was noted more often on Day 8 than on Day 16. Myometrial and endometrial/myometrial strips were incubated with LTC4 or LTD4 alone, or together with a cysteinyl-LT receptor antagonist (BAY-u9773). Leukotriene C4 increased the contraction intensity in the saline- and bacteria-treated uteri on Day 8; however, its effect was lower in the myometrium of inflamed uteri. Contraction frequency was found to decrease in the saline-treated uteri as opposed to inflamed ones, in which it was elevated. On Day 16, contraction intensity increased in response to LTC4 in the saline-treated uteri but was reduced in the inflamed organs. The value of this parameter was lower in the inflamed uteri than that in the saline-treated ones. Leukotriene D4 (Days 8 and 16) augmented contractility in the saline-treated uteri, but despite increasing its intensity in the inflamed organs, it decreased contraction frequency. Leukotriene C4 or LTD4, added to BAY-u9773-pretreated saline- and bacteria-treated uteri on both days, decreased the contraction intensity. On Day 16 after treatment with BAY-u9773 and LTC4, contraction intensity in the endometrium/myometrium of the inflamed uteri was lower than that in the saline-treated organs. Data show that both LTC4 and LTD4 affect the contractility of inflamed porcine uteri, though LTC4 exerts a weaker contractile effect.
[Mh] Termos MeSH primário: Endometrite/veterinária
Leucotrieno C4/farmacologia
Leucotrieno D4/farmacologia
Doenças dos Suínos/fisiopatologia
Contração Uterina/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Endometrite/microbiologia
Endometrite/fisiopatologia
Endométrio/fisiopatologia
Escherichia coli
Infecções por Escherichia coli/fisiopatologia
Infecções por Escherichia coli/veterinária
Feminino
Leucotrieno C4/antagonistas & inibidores
Miométrio/fisiopatologia
SRS-A/análogos & derivados
SRS-A/farmacologia
Sus scrofa
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (BAY u9773); 0 (SRS-A); 2CU6TT9V48 (Leukotriene C4); 73836-78-9 (Leukotriene D4)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:150320
[Lr] Data última revisão:
150320
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150225
[St] Status:MEDLINE


  2 / 4085 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25090924
[Au] Autor:Lenz QF; Arroyo DS; Temp FR; Poersch AB; Masson CJ; Jesse AC; Marafiga JR; Reschke CR; Iribarren P; Mello CF
[Ad] Endereço:Departamento de Fisiologia e Farmacologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil; Programa de Pós-Graduação em Farmacologia, Centro de Ciências da Saúde, Universidade Federal de Santa Maria (UFSM), Santa Maria, RS, Brazil.
[Ti] Título:Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction.
[So] Source:Neuroscience;277:859-71, 2014 Sep 26.
[Is] ISSN:1873-7544
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Current evidence suggests that inflammation plays a role in the pathophysiology of seizures. In line with this view, selected pro-inflammatory arachidonic acid derivatives have been reported to facilitate seizures. Kainate-induced seizures are accompanied by leukotriene formation, and are reduced by inhibitors of LOX/COX pathway. Moreover, LTD4 receptor blockade and LTD4 synthesis inhibition suppress pentylenetetrazol (PTZ)-induced kindling and pilocarpine-induced recurrent seizures. Although there is convincing evidence supporting that blood-brain-barrier (BBB) dysfunction facilitates seizures, no study has investigated whether the anticonvulsant effect of montelukast is associated with its ability to maintain BBB integrity. In this study we investigated whether montelukast and other CysLT receptor antagonists decrease PTZ-induced seizures, as well as whether these antagonists preserve BBB during PTZ-induced seizures. Adult male albino Swiss mice were stereotaxically implanted with a cannula into the right lateral ventricle, and two electrodes were placed over the parietal cortex along with a ground lead positioned over the nasal sinus for electroencephalography (EEG) recording. The effects of montelukast (0.03 or 0.3 µmol/1 µL, i.c.v.), pranlukast (1 or 3 µmol/1 µL, i.c.v.), Bay u-9773 (0.3, 3 or 30 nmol/1 µL, i.c.v.), in the presence or absence of the agonist LTD4 (0.2, 2, 6 or 20 pmol/1 µL, i.c.v.), on PTZ (1.8 µmol/2 µL)-induced seizures and BBB permeability disruption were determined. The animals were injected with the antagonists, agonist or vehicle 30 min before PTZ, and monitored for additional 30 min for the appearance of seizures by electrographic and behavioral methods. BBB permeability was assessed by sodium fluorescein method and by confocal microscopy for CD45 and IgG immunoreactivity. Bay-u9973 (3 and 30 nmol), montelukast (0.03 and 0.3 µmol) and pranlukast (1 and 3 µmol), increased the latency to generalized seizures and decreased the mean amplitude of EEG recordings during seizures. LTD4 (0.2 and 2 pmol) reverted the anticonvulsant effect of montelukast (0.3 µmol). Montelukast (0.03 and 0.3 µmol) prevented PTZ-induced BBB disruption, an effect that was reversed by LTD4 at the dose of 6 pmol, but not at the doses 0.2 and 2 pmol. Moreover, the doses of LTD4 (0.2 and 2 pmol) that reverted the effect of montelukast on seizures did not alter montelukast-induced protection of BBB, dissociating BBB protection and anticonvulsant activity. Confocal microscopy analysis revealed that 1. PTZ increased the number of CD45+ and double-immunofluorescence staining for CD45 and IgG cells in the cerebral cortex, indicating BBB leakage with leukocyte infiltration; 2. while LTD4 (6 pmol) potentiated, montelukast decreased the effect of PTZ on leukocyte migration and BBB, assessed by double-immunofluorescence staining for CD45 and IgG cells in the cannulated hemisphere. Our data do not allow us ruling out that mechanisms unrelated and related to BBB protection may co-exist, resulting in decreased seizure susceptibility by montelukast. Notwithstanding, they suggest that CysLT1 receptors may be a suitable target for anticonvulsant development.
[Mh] Termos MeSH primário: Anticonvulsivantes/farmacologia
Barreira Hematoencefálica/efeitos dos fármacos
Encéfalo/efeitos dos fármacos
Antagonistas de Leucotrienos/farmacologia
Fármacos Neuroprotetores/farmacologia
Convulsões/tratamento farmacológico
[Mh] Termos MeSH secundário: Acetatos/farmacologia
Animais
Barreira Hematoencefálica/fisiopatologia
Encéfalo/fisiopatologia
Permeabilidade Capilar/efeitos dos fármacos
Permeabilidade Capilar/fisiologia
Cromonas/farmacologia
Relação Dose-Resposta a Droga
Imunoglobulina G/metabolismo
Antígenos Comuns de Leucócito/metabolismo
Leucócitos/efeitos dos fármacos
Leucócitos/fisiologia
Leucotrieno D4/farmacologia
Masculino
Camundongos
Pentilenotetrazol
Quinolinas/farmacologia
Receptores de Leucotrienos/agonistas
Receptores de Leucotrienos/metabolismo
SRS-A/análogos & derivados
SRS-A/farmacologia
Convulsões/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetates); 0 (Anticonvulsants); 0 (BAY u9773); 0 (Chromones); 0 (Immunoglobulin G); 0 (Leukotriene Antagonists); 0 (Neuroprotective Agents); 0 (Quinolines); 0 (Receptors, Leukotriene); 0 (SRS-A); 0 (leukotriene D4 receptor); 73836-78-9 (Leukotriene D4); EC 3.1.3.48 (Leukocyte Common Antigens); EC 3.1.3.48 (Ptprc protein, mouse); MHM278SD3E (montelukast); TB8Z891092 (pranlukast); WM5Z385K7T (Pentylenetetrazole)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140806
[St] Status:MEDLINE


  3 / 4085 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23801612
[Au] Autor:Zhang Z; Luo J; Huang J; Liu Z; Fang S; Zhang WP; Wei E; Lu Y
[Ad] Endereço:Department of Pharmacology, Zhejiang University School of Medicine, Key Laboratory of Medical Neurobiology of Ministry of Health, Hangzhou 310058, China.
[Ti] Título:[Leukotriene D4 activates BV2 microglia in vitro].
[So] Source:Zhejiang Da Xue Xue Bao Yi Xue Ban;42(3):253-60, 2013 May.
[Is] ISSN:1008-9292
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To investigate the effects of CysLT receptor agonist leukotriene D4(LTD4) and antagonists on activation of microglia BV2 cells. METHODS: The expression of CysLT1 and CysLT2 protein was determined by Western blotting and immunostaining in microglia BV2 cells. BV2 cells were pretreated with or without CysLT1 receptor selective antagonist montelukast, CysLT2 receptor selective antagonist HAMI 3379, or CysLT1/CysLT2 receptor dual antagonist BAY u9773 for 30 min, then the cells were treated with LTD4 for 24 h. Cell viability was detected by MTT reduction assay. Phagocytosis and mRNA expression of IL-6 were determined by fluorescent bead tracking and RT-PCR, respectively. RESULTS: In BV2 cells, LTD4 did not affect proliferation but significantly enhanced phagocytosis and increased IL-6 mRNA expression in a concentration-dependent manner. LTD4 at 100 nmol/L induced a 1.4-fold increase of phagocytic index and a 2-fold up-regulation of IL-6 mRNA expression (P<0.01). HAMI 3379 and BAY u9773 (100 nmol/L) further increased LTD4-induced phagocytosis; BAY u9773 and montelukast decreased LTD4-induced IL-6 mRNA expression, while HAMI 3379 had no effect on that. CONCLUSION: LTD4 activates BV2 cells in vitro and enhances IL-6 mRNA expression mediated by CysLT1 receptor, LTD4 induces phagocytosis which might be negatively regulated by CysLT2 receptor in BV2 cells.
[Mh] Termos MeSH primário: Leucotrieno D4/farmacologia
Microglia/citologia
Receptores de Leucotrienos/metabolismo
[Mh] Termos MeSH secundário: Acetatos/farmacologia
Linhagem Celular
Proliferação Celular
Ácidos Cicloexanocarboxílicos/farmacologia
Seres Humanos
Interleucina-6/metabolismo
Antagonistas de Leucotrienos/farmacologia
Microglia/metabolismo
Fagocitose
Ácidos Ftálicos/farmacologia
Quinolinas/farmacologia
SRS-A/análogos & derivados
SRS-A/farmacologia
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-(cyclohexyloxy)butoxy)phenyl)propoxy)benzoic acid); 0 (Acetates); 0 (BAY u9773); 0 (Cyclohexanecarboxylic Acids); 0 (IL6 protein, human); 0 (Interleukin-6); 0 (Leukotriene Antagonists); 0 (Phthalic Acids); 0 (Quinolines); 0 (Receptors, Leukotriene); 0 (SRS-A); 0 (cysteinyl leukotriene receptor 2); 0 (leukotriene D4 receptor); 73836-78-9 (Leukotriene D4); MHM278SD3E (montelukast)
[Em] Mês de entrada:1401
[Cu] Atualização por classe:130626
[Lr] Data última revisão:
130626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130627
[St] Status:MEDLINE


  4 / 4085 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21903747
[Au] Autor:Ni NC; Yan D; Ballantyne LL; Barajas-Espinosa A; St Amand T; Pratt DA; Funk CD
[Ad] Endereço:Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
[Ti] Título:A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice.
[So] Source:J Pharmacol Exp Ther;339(3):768-78, 2011 Dec.
[Is] ISSN:1521-0103
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cysteinyl leukotrienes (CysLTs) are potent inflammatory mediators that predominantly exert their effects by binding to cysteinyl leukotriene receptors of the G protein-coupled receptor family. CysLT receptor 2 (CysLT(2)R), expressed in endothelial cells of some vascular beds, has been implicated in a variety of cardiovascular functions. Endothelium-specific overexpression of human CysLT(2)R in transgenic mice (hEC-CysLT(2)R) greatly increases myocardial infarction damage. Investigation of this receptor, however, has been hindered by the lack of selective pharmacological antagonists. Here, we describe the characterization of 3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)-propoxy)benzoic acid (BayCysLT(2)) and explore the selective effects of this compound in attenuating myocardial ischemia/reperfusion damage and vascular leakage. Using a recently developed ß-galactosidase-ß-arrestin complementation assay for CysLT(2)R activity (Mol Pharmacol 79:270-278, 2011), we determined BayCysLT(2) to be ∼20-fold more potent than the nonselective dual CysLT receptor 1 (CysLT(1)R)/CysLT(2)R antagonist 4-(((1R,2E,4E,6Z,9Z)-1-((1S)-4-carboxy-1-hydroxybutyl)-2,4,6,9-pentadecatetraen-1-yl)thio)benzoic acid (Bay-u9773) (IC(50) 274 nM versus 4.6 µM, respectively). Intracellular calcium mobilization in response to cysteinyl leukotriene administration showed that BayCysLT(2) was >500-fold more selective for CysLT(2)R compared with CysLT(1)R. Intraperitoneal injection of BayCysLT(2) in mice significantly attenuated leukotriene D(4)-induced Evans blue dye leakage in the murine ear vasculature. BayCysLT(2) administration either before or after ischemia/reperfusion attenuated the aforementioned increased myocardial infarction damage in hEC-CysLT(2)R mice. Finally, decreased neutrophil infiltration and leukocyte adhesion molecule mRNA expression were observed in mice treated with antagonist compared with untreated controls. In conclusion, we present the characterization of a potent and selective antagonist for CysLT(2)R that is useful for discerning biological activities of this receptor.
[Mh] Termos MeSH primário: Permeabilidade Capilar/efeitos dos fármacos
Ácidos Cicloexanocarboxílicos/farmacologia
Antagonistas de Leucotrienos/farmacologia
Leucotrieno D4/antagonistas & inibidores
Infarto do Miocárdio/tratamento farmacológico
Traumatismo por Reperfusão Miocárdica/tratamento farmacológico
Ácidos Ftálicos/farmacologia
Receptores de Leucotrienos/metabolismo
SRS-A/análogos & derivados
[Mh] Termos MeSH secundário: Animais
Arrestinas/análise
Modelos Animais de Doenças
Avaliação Pré-Clínica de Medicamentos
Orelha/irrigação sanguínea
Seres Humanos
Camundongos
Camundongos Transgênicos
Infarto do Miocárdio/metabolismo
Traumatismo por Reperfusão Miocárdica/fisiopatologia
Miocárdio/patologia
Miócitos Cardíacos/efeitos dos fármacos
Peroxidase/metabolismo
SRS-A/farmacologia
beta-Arrestinas
beta-Galactosidase/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)propoxy)benzoic acid); 0 (Arrestins); 0 (BAY u9773); 0 (Cyclohexanecarboxylic Acids); 0 (Leukotriene Antagonists); 0 (Phthalic Acids); 0 (Receptors, Leukotriene); 0 (SRS-A); 0 (beta-Arrestins); 0 (cysteinyl leukotriene receptor 2); 73836-78-9 (Leukotriene D4); EC 1.11.1.7 (Peroxidase); EC 3.2.1.23 (beta-Galactosidase)
[Em] Mês de entrada:1201
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110910
[St] Status:MEDLINE
[do] DOI:10.1124/jpet.111.186031


  5 / 4085 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21680952
[Au] Autor:Chawes BL; Bønnelykke K; Bisgaard H
[Ad] Endereço:Copenhagen Prospective Studies on Asthma in Childhood, Health Sciences, University of Copenhagen, Copenhagen, Denmark
[Ti] Título:Elevated eosinophil protein X in urine from healthy neonates precedes development of atopy in the first 6 years of life.
[So] Source:Am J Respir Crit Care Med;184(6):656-61, 2011 Sep 15.
[Is] ISSN:1535-4970
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Biomarkers predicting development of atopic disease are needed for targeted preventive measures and to study if disease pathology may be active before onset of symptoms. OBJECTIVES: To investigate whether eosinophil protein X, leukotriene-C4/D4/E4, and 11ß-prostaglandin (PG) F2α (PGD2 metabolite) assessed in urine from healthy at-risk neonates precede development of atopic disease during the first 6 years of life. METHODS: We measured eosinophil protein X (n = 369), leukotriene-C4/D4/E4 (n = 367), and 11ß-PGF2α (n = 366) in urine from 1-month-old children participating in the Copenhagen Prospective Studies on Asthma in Childhood birth cohort. Clinical data on development of allergic sensitization, allergic rhinitis, nasal eosinophilia, blood eosinophilia, eczema, troublesome lung symptoms (significant cough or wheeze or dyspnea), and asthma were collected prospectively until age 6 years. Associations between urinary biomarkers and development of atopic traits were investigated using general estimating equations, logistic regression, and Cox regression. MEASUREMENTS AND MAIN RESULTS: Eosinophil protein X in the urine of the asymptomatic 1-month-old neonates was significantly associated with development of allergic sensitization (odds ratio, 1.49; 95% confidence interval [CI], 1.08­1.89), nasal eosinophilia (odds ratio, 3.2; 95% CI, 1.2­8.8), and eczema (hazard ratio, 1.4; 95% CI, 1.0­2.0), but not with allergic rhinitis, asthma, or blood eosinophilia. Neither leukotriene-C4/D4/E4 nor 11ß-PGF2α was associated with any of the atopic phenotypes. CONCLUSIONS: Eosinophil protein X in urine from asymptomatic neonates is a biomarker significantly associated with later development of allergic sensitization, nasal eosinophilia, and eczema during the first 6 years of life. These findings suggest activation of eosinophil granulocytes early in life before development of atopy-related symptoms.
[Mh] Termos MeSH primário: Neurotoxina Derivada de Eosinófilo/urina
Hipersensibilidade Imediata/urina
[Mh] Termos MeSH secundário: Biomarcadores/urina
Criança
Pré-Escolar
Estudos de Coortes
Feminino
Seres Humanos
Lactente
Recém-Nascido
Masculino
Razão de Chances
Prostaglandinas/urina
SRS-A/urina
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers); 0 (Prostaglandins); 0 (SRS-A); EC 3.1.- (Eosinophil-Derived Neurotoxin); EC 3.1.27.5 (RNASE2 protein, human)
[Em] Mês de entrada:1201
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:110618
[St] Status:MEDLINE
[do] DOI:10.1164/rccm.201101-0111OC


  6 / 4085 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21646802
[Au] Autor:Muraki M; Imbe S; Santo H; Sato R; Sano H; Iwanaga T; Tohda Y
[Ad] Endereço:Department of Respiratory Medicine and Allergology, Nara Hospital, Kinki University Faculty of Medicine, Ikoma, Japan. muraki@nara.med.kindai.ac.jp
[Ti] Título:Effects of a cysteinyl leukotriene dual 1/2 receptor antagonist on antigen-induced airway hypersensitivity and airway inflammation in a guinea pig asthma model.
[So] Source:Int Arch Allergy Immunol;155 Suppl 1:90-5, 2011.
[Is] ISSN:1423-0097
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Little is known about the role of the cysteinyl leukotriene (cysLT) 2 receptor in the pathophysiology of asthma. The aim of this study is to investigate the effects of a cysLT1 receptor antagonist (montelukast) and a dual cysLT1/2 receptor antagonist (BAY-u9773) on airway hypersensitivity and airway inflammation induced by antigen challenge in ovalbumin (OVA)-sensitized guinea pigs. METHODS: Male Hartley guinea pigs sensitized with OVA were intraperitoneally administered 0.1, 1, or 10 mg/kg of montelukast or 0.1 mg/kg of BAY-u9773 and then challenged with inhaled OVA. Airway reactivity to acetylcholine, inflammatory cells in bronchoalveolar lavage (BAL) fluid, and eosinophil infiltration in airway walls after OVA challenge were evaluated. RESULTS: Pretreatment with 1 or 10 mg/kg, but not 0.1 mg/kg, of montelukast significantly suppressed airway hypersensitivity and eosinophil infiltration into the BAL fluid. Moreover, 0.1 mg/kg of BAY-u9773 significantly suppressed the development of these markers. The suppressive effects of BAY-u9773, although not significantly different, trended toward being greater than those of montelukast. Although all of the doses of montelukast tested and 0.1 mg/kg of BAY-u9773 significantly suppressed eosinophil infiltration in airway walls, the suppressive effect of BAY-u9773 was significantly greater than that of 0.1 mg/kg of montelukast. CONCLUSION: Signaling may contribute to the pathophysiology of asthma via the cysLT1/2 receptor.
[Mh] Termos MeSH primário: Asma/tratamento farmacológico
Hiper-Reatividade Brônquica/prevenção & controle
Antagonistas de Leucotrienos/uso terapêutico
Receptores de Leucotrienos
[Mh] Termos MeSH secundário: Acetatos/farmacologia
Acetatos/uso terapêutico
Acetilcolina/farmacologia
Animais
Asma/induzido quimicamente
Asma/imunologia
Asma/patologia
Asma/fisiopatologia
Hiper-Reatividade Brônquica/fisiopatologia
Testes de Provocação Brônquica
Líquido da Lavagem Broncoalveolar/citologia
Eosinófilos/patologia
Cobaias
Inflamação/patologia
Inflamação/prevenção & controle
Antagonistas de Leucotrienos/farmacologia
Pulmão/efeitos dos fármacos
Pulmão/patologia
Pulmão/fisiopatologia
Masculino
Ovalbumina/administração & dosagem
Ovalbumina/imunologia
Quinolinas/farmacologia
Quinolinas/uso terapêutico
SRS-A/análogos & derivados
SRS-A/farmacologia
SRS-A/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetates); 0 (BAY u9773); 0 (Leukotriene Antagonists); 0 (Quinolines); 0 (Receptors, Leukotriene); 0 (SRS-A); 0 (cysteinyl leukotriene receptor 2); 0 (leukotriene D4 receptor); 9006-59-1 (Ovalbumin); MHM278SD3E (montelukast); N9YNS0M02X (Acetylcholine)
[Em] Mês de entrada:1107
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110608
[St] Status:MEDLINE
[do] DOI:10.1159/000327439


  7 / 4085 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21396378
[Au] Autor:Huang SC
[Ad] Endereço:Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Hospital, and School of Chinese Medicine for Post-Baccalaureate, I-Shou University, Kaohsiung, Taiwan. shihchehuang@hotmail.com
[Ti] Título:Leukotriene-induced contraction is mediated by cysteinyl leukotriene receptor CysLT1 in guinea pig fundus but by CysLT1 and CysLT2 in antrum.
[So] Source:Life Sci;88(17-18):819-24, 2011 Apr 25.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Leukotriene D(4) (LTD(4)) causes contraction of the stomach through unclear receptors. The aim of the present study is to characterize the cysteinyl leukotriene receptor (CysLT) mediating leukotriene-induced muscle contraction in the stomach. MAIN METHODS: We measured contraction of gastric muscle strips isolated from the guinea pig fundus and antrum caused by cysteinyl leukotrienes, including LTC(4), LTD(4) and LTE(4), as well as the dihydroxy leukotriene LTB(4) in vitro. KEY FINDINGS: In both fundic and antral muscle strips, LTC(4) and LTD(4) caused marked whereas LTE(4) caused moderate, concentration-dependent contractions. In contrast, LTB(4) caused only small contraction. The relative potencies for cysteinyl leukotrienes to cause contraction in both fundus and antrum were LTC(4)=LTD(4)>LTE(4). The LTD(4)-induced contraction was not affected by tetrodotoxin or atropine, suggesting that the action is not neurally mediated. The LTD(4)-induced contraction in the fundus was almost abolished by the CysLT(1) selective antagonist montelukast. In contrast, the LTD(4)-induced contraction in the antrum was only partially inhibited by montelukast or the dual CysLT(1) and CysLT(2) antagonist BAY u9773. This antral contraction was almost abolished by the combination of montelukast and BAY u9773, indicating enhancement of inhibition. SIGNIFICANCE: The results of the present study demonstrate that cysteinyl leukotrienes LTC(4), LTD(4) and LTE(4) cause moderate to marked whereas the dihydroxy leukotriene LTB(4) causes small muscle contraction in the stomach in vitro. The leukotriene-induced contraction is mediated by CysLT(1) in fundus but by CysLT(1) and CysLT(2) in antrum.
[Mh] Termos MeSH primário: Fundo Gástrico/efeitos dos fármacos
Leucotrieno D4/farmacologia
Contração Muscular/efeitos dos fármacos
Antro Pilórico/efeitos dos fármacos
Receptores de Leucotrienos/fisiologia
[Mh] Termos MeSH secundário: Acetatos/farmacologia
Animais
Relação Dose-Resposta a Droga
Fundo Gástrico/fisiologia
Cobaias
Leucotrieno C4/farmacologia
Leucotrieno E4/farmacologia
Masculino
Contração Muscular/fisiologia
Antro Pilórico/fisiologia
Quinolinas/farmacologia
Receptores de Leucotrienos/efeitos dos fármacos
SRS-A/análogos & derivados
SRS-A/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Acetates); 0 (BAY u9773); 0 (Quinolines); 0 (Receptors, Leukotriene); 0 (SRS-A); 0 (leukotriene D4 receptor); 2CU6TT9V48 (Leukotriene C4); 73836-78-9 (Leukotriene D4); 75715-89-8 (Leukotriene E4); MHM278SD3E (montelukast)
[Em] Mês de entrada:1106
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110315
[St] Status:MEDLINE
[do] DOI:10.1016/j.lfs.2011.02.023


  8 / 4085 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21055410
[Au] Autor:Qi LL; Fang SH; Shi WZ; Huang XQ; Zhang XY; Lu YB; Zhang WP; Wei EQ
[Ad] Endereço:Institute of Neuroscience and Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China.
[Ti] Título:CysLT2 receptor-mediated AQP4 up-regulation is involved in ischemic-like injury through activation of ERK and p38 MAPK in rat astrocytes.
[So] Source:Life Sci;88(1-2):50-6, 2011 Jan 03.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: We previously reported that cysteinyl leukotriene receptor 2 (CysLT(2)) mediates ischemic astrocyte injury, and leukotriene D(4)-activated CysLT(2) receptor up-regulates the water channel aquaporin 4 (AQP4). Here we investigated the mechanism underlying CysLT(2) receptor-mediated ischemic astrocyte injury induced by 4-h oxygen-glucose deprivation and 24-h recovery (OGD/R). MAIN METHODS: Primary cultures of rat astrocytes were treated by OGD/R to construct the cell injury model. AQP4 expression was inhibited by small interfering RNA (siRNA). The expressions of AQP4 and CysLTs receptors, and the MAPK signaling pathway were determined. KEY FINDINGS: OGD/R induced astrocyte injury, and increased expression of the CysLT(2) (but not CysLT(1)) receptor and AQP4. OGD/R-induced cell injury and AQP4 up-regulation were inhibited by a CysLT(2) receptor antagonist (Bay cysLT2) and a non-selective CysLT receptor antagonist (Bay u9773), but not by a CysLT(1) receptor antagonist (montelukast). Knockdown of AQP4 by siRNA attenuated OGD/R injury. Furthermore, OGD/R increased phosphorylation of ERK1/2 and p38, whose inhibitors relieved the cell injury and AQP4 up-regulation. SIGNIFICANCE: The CysLT(2) receptor mediates AQP4 up-regulation in astrocytes, and up-regulated AQP4 leads to OGD/R-induced injury, which results from activation of the ERK1/2 and p38 MAPK pathways.
[Mh] Termos MeSH primário: Aquaporina 4/fisiologia
Astrócitos/enzimologia
Isquemia Encefálica/metabolismo
MAP Quinases Reguladas por Sinal Extracelular/metabolismo
Receptores de Leucotrienos/fisiologia
Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
[Mh] Termos MeSH secundário: Animais
Aquaporina 4/biossíntese
Astrócitos/metabolismo
Astrócitos/fisiologia
Western Blotting
Isquemia Encefálica/enzimologia
Isquemia Encefálica/fisiopatologia
Células Cultivadas
Ativação Enzimática/efeitos dos fármacos
Fosforilação
Ratos
Ratos Sprague-Dawley
Receptores de Leucotrienos/efeitos dos fármacos
Receptores de Leucotrienos/metabolismo
Reação em Cadeia da Polimerase Via Transcriptase Reversa
SRS-A/análogos & derivados
SRS-A/farmacologia
Transdução de Sinais/efeitos dos fármacos
Transdução de Sinais/fisiologia
Regulação para Cima/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Aquaporin 4); 0 (BAY u9773); 0 (Receptors, Leukotriene); 0 (SRS-A); 0 (cysteinyl leukotriene receptor 2); EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases); EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
[Em] Mês de entrada:1101
[Cu] Atualização por classe:101227
[Lr] Data última revisão:
101227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101109
[St] Status:MEDLINE
[do] DOI:10.1016/j.lfs.2010.10.025


  9 / 4085 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20226503
[Au] Autor:Cohen SG; Mazzullo JC
[Ti] Título:Slow reactive substance of anaphylaxis.
[So] Source:J Allergy Clin Immunol;125(4):950-1; author reply 951, 2010 Apr.
[Is] ISSN:1097-6825
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anafilaxia/fisiopatologia
SRS-A/metabolismo
[Mh] Termos MeSH secundário: Anafilaxia/metabolismo
Animais
Gatos
Seres Humanos
Músculo Liso/fisiologia
Coelhos
Espasmo/etiologia
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (SRS-A)
[Em] Mês de entrada:1004
[Cu] Atualização por classe:100407
[Lr] Data última revisão:
100407
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:100316
[St] Status:MEDLINE
[do] DOI:10.1016/j.jaci.2009.12.940


  10 / 4085 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:19941848
[Au] Autor:Chebolu S; Wang Y; Ray AP; Darmani NA
[Ad] Endereço:Department of Basic Medical Science, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA. schebolu@westernu.edu
[Ti] Título:Pranlukast prevents cysteinyl leukotriene-induced emesis in the least shrew (Cryptotis parva).
[So] Source:Eur J Pharmacol;628(1-3):195-201, 2010 Feb 25.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Many chemotherapeutic agents activate multiple signaling systems, including potentially emetogenic arachidonic acid metabolites. Of these messengers, the emetic role of the leukotriene family has been neglected. The aims of this study were to test the emetic potential of key leukotrienes (LTA(4), LTB(4), LTF(4), and the cysteinyl leukotrienes LTC(4), LTD(4) and LTE(4)), and to investigate whether the leukotriene CysLT(1) receptor antagonist pranlukast or mixed leukotriene CysLT(1/2) receptor antagonist Bay u9773 can prevent the LTC(4)-induced emesis. Least shrews were injected with varying doses of one of the six tested leukotrienes and vomiting parameters were measured for 30min. LTC(4) and LTD(4) were most efficacious, and significantly increased both the frequency and percentage of animals vomiting at doses from 0.1 and 0.05mg/kg, respectively. The other tested leukotrienes were either weakly emetic or ineffective at doses up to 4mg/kg. The relative emetogenic activities of the cysteinyl leukotrienes (LTC(4)=LTD(4)>LTE(4)) suggest that leukotriene CysLT(2) receptors have a key role in emesis. However, pranlukast dose-dependently, and at 10mg/kg completely, blocked LTC(4)-induced vomiting, implicating a leukotriene CysLT(1) receptor-mediated emetic effect. Bay u9773 dose-dependently reduced the percentage of animals vomiting, but did not significantly reduce vomiting frequency. Fos immunoreactivity, measured subsequent to LTC(4)-induced vomiting to define its putative anatomical substrates, was significantly increased in the enteric nervous system and medullary dorsal vagal complex following LTC(4) (P<0.05) versus vehicle injections. This study is the first to show that some leukotrienes induce emesis, possibly involving both central and peripheral leukotriene CysLT(1) and/or leukotriene CysLT(2) receptors.
[Mh] Termos MeSH primário: Cromonas/farmacologia
Cisteína/efeitos adversos
Insetívoros
Leucotrienos/efeitos adversos
Vômito/induzido quimicamente
Vômito/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Cromonas/uso terapêutico
Relação Dose-Resposta a Droga
Feminino
Imuno-Histoquímica
Injeções
Leucotrieno C4/administração & dosagem
Leucotrieno C4/efeitos adversos
Masculino
Proteínas Proto-Oncogênicas c-fos/metabolismo
SRS-A/análogos & derivados
SRS-A/farmacologia
Vômito/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (BAY u9773); 0 (Chromones); 0 (Leukotrienes); 0 (Proto-Oncogene Proteins c-fos); 0 (SRS-A); 0 (cysteinyl-leukotriene); 2CU6TT9V48 (Leukotriene C4); K848JZ4886 (Cysteine); TB8Z891092 (pranlukast)
[Em] Mês de entrada:1004
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:091128
[St] Status:MEDLINE
[do] DOI:10.1016/j.ejphar.2009.11.030



página 1 de 409 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde